These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28549534)

  • 21. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience.
    Sheikh-Taha M
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):59-64. PubMed ID: 30203330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report.
    Tireli D; He J; Nordling MM; Wienecke T
    J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):e123-e125. PubMed ID: 28479184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal of Dabigatran with Idarucizumab.
    Sodha NR; Sellke FW
    Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):889-93. PubMed ID: 27362456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probable drug-drug interaction between dabigatran and quinidine resulting in thrombin time rebound despite multiple idarucizumab doses.
    George S; Taburyanskaya M; Lewis V
    Blood Coagul Fibrinolysis; 2019 Jan; 30(1):42-46. PubMed ID: 30431448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Idarucizumab: First Global Approval.
    Burness CB
    Drugs; 2015 Dec; 75(18):2155-61. PubMed ID: 26578027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
    Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
    J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. idarucizumab (PRAXBIND°). Don't rely too heavily on this dabigatran antidote.
    Prescrire Int; 2016 Nov; 25(176):260-263. PubMed ID: 30715821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Refractory Dabigatran-Induced Hemorrhage Despite Multiple Idarucizumab Administration and Renal Replacement Therapy.
    Flynn F; Richard G; Dobrescu MA; Bouchard J; Williamson D; Brindamour D; Charbonney E; Dupuis S
    J Pharm Pract; 2022 Apr; 35(2):302-307. PubMed ID: 32985337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dabigatran-induced nephropathy and its successful treatment with Idarucizumab - case report and literature review.
    Awesat J; Sagy I; Haviv YS; Rabinovich A; Jotkowitz A; Shleyfer E; Barski L
    Thromb Res; 2018 Sep; 169():120-122. PubMed ID: 30032039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
    Thibault N; Morrill AM; Willett KC
    Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis.
    Comuth WJ; Haase AM; Henriksen LØ; Malczynski J; van de Kerkhof D; Münster AB
    Scand J Clin Lab Invest; 2018; 78(1-2):1-5. PubMed ID: 29148292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
    Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
    Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dabigatran Reversal With Idarucizumab Preceding Thrombolysis in an Octogenarian Patient with Chronic Kidney Disease and Acute Stroke: A Case Report.
    Laxamana LC; Co COC; Yu JRT; Mojica CV; Iboleon-Dy MAM; Domingo AMC; Ilano KCS; Macrohon-Valdez MCZ
    Clin Ther; 2020 Sep; 42(9):1840-1845. PubMed ID: 32778345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dabigatran use in elderly patients with atrial fibrillation.
    Avgil-Tsadok M; Jackevicius CA; Essebag V; Eisenberg MJ; Rahme E; Behlouli H; Pilote L
    Thromb Haemost; 2016 Jan; 115(1):152-60. PubMed ID: 26354766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience.
    Kumar R; Smith RE; Henry BL
    J Intensive Care Med; 2015 Dec; 30(8):462-72. PubMed ID: 24668159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Management of bleeding associated with direct oral anticoagulants: update on reversal strategies].
    Enríquez A; Baranchuk A; Corbalán R
    Rev Med Chil; 2019; 147(1):73-82. PubMed ID: 30848768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
    Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
    Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of dabigatran according to age in atrial fibrillation.
    Lauw MN; Eikelboom JW; Coppens M; Wallentin L; Yusuf S; Ezekowitz M; Oldgren J; Nakamya J; Wang J; Connolly SJ
    Heart; 2017 Jul; 103(13):1015-1023. PubMed ID: 28213368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.